Abbott Looks To Xinlay Back-Up Study After Negative Advisory Cmte. Review
Executive Summary
Abbott is counting on its back-up Phase III study to support Xinlay approval should FDA follow the recommendation of its Oncologic Drugs Advisory Committee and reject the current application
You may also be interested in...
Unresolved Review Issues: Clinical Trials Are Easier Fix Than Safety, Efficacy
Problems with clinical trial design and/or execution identified pre-submission are the issues most likely to be resolved in advance of first FDA action, Booz Allen Hamilton's first-cycle review report finds
Unresolved Review Issues: Clinical Trials Are Easier Fix Than Safety, Efficacy
Problems with clinical trial design and/or execution identified pre-submission are the issues most likely to be resolved in advance of first FDA action, Booz Allen Hamilton's first-cycle review report finds
Generics Infringe On Branded Stock Growth As Investors Eye Mergers, Part D
Generic drug consolidation and the pending implementation of Medicare Part D in January, with its cost pressures likely to benefit unbranded drugs, appear to be swaying investor confidence in favor of generic drug makers